MAGNETIC MICROCLUSTERS FOR MRI CONTRAST AGENTS

人们发现了一类新型材料， 行为在其本机（子50A）状态，但当组装成集群的 直径大于500的样品表现出超顺磁性行为。 材料 这种类型可以制备成可生物降解的500A簇，注入到 作为安全、无毒、可降解的MRI造影剂。 一 提出了利用这些磁性团簇作为药剂的研究方案 对于MRI造影，构建各种大小的簇，用于大小排除 输送到特定器官进行MRI对比，并研究60Hz 这些簇的RP磁场响应与簇大小、时间、pH 和温度 Omni Quest承认需要进行体内试验，以确定 其研究的可行性，虽然这样的计划是不可行的， 一个“小企业”，一个生物技术公司， 将对候选材料进行分析，并制定战略计划， 完成体内测试。 基于第一阶段的成功，Omni Quest已经进入了 与重要国际机构签订研究合作协议 制药公司和研究中心，有能力， 旨在进行动物体内试验。 这些机密 关系将在本文件的受保护部分中披露。 只有建议。

A novel class of material has been discovered that exhibits non-magnetic behavior in its native (sub 50A) state, but when assembled into clusters of above 500A in diameter exhibits superparamagnetic behavior. Materials of this type can be prepared as biodegradable 500A clusters, injected into patients and used as safe, non-toxic, degradable MRI contrast agents. A research program is proposed to utilize these magnetic clusters as agents for MRI contrast, to build clusters of various sizes for size exclusion delivery to specific organs for contrasting in MRI and to study the 60Hz and RP magnetic field response of these clusters vs. cluster size, time, pH and temperature. Omni Quest acknowledges the need for in vivo testing to determine the viability of its research and while such a program is not feasible within the limits of a Phase I proposal by a "small business", a biological analysis of candidate materials will be conducted and a strategic plan for accomplishing in vivo testing is in place. Based upon a successful Phase I, Omni Quest has already entered into research collaboration agreements with significant international pharmaceutical companies and research centers that have the ability and intent to conduct in vivo testing in animals. These confidential relationships will be disclosed within the protected portion of this proposal only.